Články s príkazom na verejný prístup - Adrián LLerena MD PhD Professor Clinical PharmacologyĎalšie informácie
Nedostupné nikde: 29
CYP2D6 Genotyping for Psychiatric Patients Treated with Risperidone: Considerations for Cost–Effectiveness Studies
C Rodriguez-Antona, D Gurwitz, J De Leon, A Llerena, J Kirchheiner, ...
Pharmacogenomics 10 (4), 685-699, 2009
Príkazy: US National Institutes of Health
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients
EM Penas-Lledo, HD Trejo, P Dorado, A Ortega, H Jung, E Alonso, ...
Molecular psychiatry 18 (1), 8-9, 2013
Príkazy: Government of Spain
Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF …
MEG Naranjo, F Rodrigues-Soares, EM Penas-Lledo, E Tarazona-Santos, ...
Omics: a journal of integrative biology 22 (9), 575-588, 2018
Príkazy: Government of Spain
CYP2D6 and The Severity of Suicide Attempts
EM Penas-Lledo, H Blasco-Fontecilla, P Dorado, C Vaquero-Lorenzo, ...
Pharmacogenomics 13 (2), 179-184, 2012
Príkazy: Government of Spain
Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain
A Llerena, M Alvarez, P Dorado, I González, E Peñas-LLedó, B Pérez, ...
The pharmacogenomics journal 14 (3), 229-234, 2014
Príkazy: Government of Spain
A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
E Peñas-Lledó, S Guillaume, MEG Naranjo, A Delgado, I Jaussent, ...
The pharmacogenomics journal 15 (2), 172-176, 2015
Príkazy: Government of Spain
Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6
N González-Vacarezza, F Abad-Santos, A Carcas-Sansuan, P Dorado, ...
The pharmacogenomics journal 13 (5), 452-455, 2013
Príkazy: Government of Spain
Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response
NM Jaramillo, IF Galindo, AO Vázquez, HJ Cook, A LLerena, ML López
Drug metabolism and drug interactions 29 (2), 67-79, 2014
Príkazy: Government of Spain
CYP2D6 -1584C>G Promoter Polymorphism and Debrisoquine Ultrarapid Hydroxylation in Healthy Volunteers
A LLerena, P Dorado, R Ramirez, LR Calzadilla, E Penas-LLedo, ...
Pharmacogenomics 14 (16), 1973-1977, 2013
Príkazy: Government of Spain
Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study
S Mas, A LLerena, J Saiz, M Bernardo, A Lafuente
Pharmacogenomics 13 (15), 1773-1782, 2012
Príkazy: Government of Spain
CYP2D6Genetic Polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
M Lopez-Lopez, E Penas-Lledo, P Dorado, A Ortega, T Corona, A Ochoa, ...
Pharmacogenomics 15 (15), 1859-1865, 2014
Príkazy: Government of Spain
Relationship between the CYP2C9 IVS8-109A>T Polymorphism and High Losartan Hydroxylation in Healthy Ecuadorian Volunteers
P Dorado, A Gallego, E Peñas-LLedó, E Terán, A LLerena
Pharmacogenomics 15 (11), 1417-1421, 2014
Príkazy: Government of Spain
ABCB1 gene polymorphisms and violent suicide attempt among survivors
E Peñas-Lledó, S Guillaume, A Delgado, MEG Naranjo, I Jaussent, ...
Journal of Psychiatric Research 61, 52-56, 2015
Príkazy: Government of Spain
Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis
P Gassó, S Mas, M Bioque, B Cabrera, A Lobo, A Gonzalez-Pinto, ...
Journal of Psychopharmacology 32 (6), 702-710, 2018
Príkazy: Government of Spain
Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
I Rodeiro, D Remírez-Figueredo, M García-Mesa, P Dorado, A LLerena, ...
Walter de Gruyter 27 (1), 57-60, 2012
Príkazy: Government of Spain
Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.
GMCFPCIAPPR Albuquerque J, Ribeiro C, Naranjo MEG, Llerena A
Personalized Medicine 10 (7), 709-718, 2013
Príkazy: Government of Spain
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-Limited Settings: Conclusions from the Council for International Organizations of Medical …
E Peñas-LLedó, E Terán, M Sosa-Macías, C Galaviz-Hernández, JP Gil, ...
Clinical Therapeutics 42 (8), 1595-1610. e5, 2020
Príkazy: Government of Spain
Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
P Dorado, E Machín, F de Andrés, MEG Naranjo, EM Peñas-Lledó, ...
Drug Metabolism and Drug Interactions 27 (4), 217-223, 2012
Príkazy: Government of Spain
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
I Fricke-Galindo, A Ortega-Vázquez, N Monroy-Jaramillo, P Dorado, ...
Pharmacogenomics 17 (17), 1913-1930, 2016
Príkazy: Government of Spain
Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-) genetic factors.
P Magalhães, G Alves, A Fortuna, A Llerena, A Falcão
Experimental and Clinical Psychopharmacology 28 (5), 589, 2020
Príkazy: Fundação para a Ciência e a Tecnologia, Portugal
Informácie o zverejnení a financovaní sú automaticky vyberané počítačovým programom